Hemab Therapeutics (COAG) Q3 2026 earnings review
Hemab advances three bleeding drugs, but skips FDA trial advice
Hemab Therapeutics, a clinical-stage developer of drugs for blood clotting disorders, advanced all three of its medicines while taking on new regulatory risk. Chief executive Benny Sørensen started a Phase 3 study for lead drug sutacimig and dosed the first volunteer in a Phase 1 trial for HMB-003. Expanding these human trials pushed quarterly research spending up 69% to $25 million and left $430 million in the bank. By our math, the company's plan to fund operations into 2029 allows quarterly cash burn to rise past $43 million.
| Cash and marketable securities | $430.2M $457.5M last quarter |
|---|---|
| Research and development spending | $24.6M +69% from a year ago |
| Operating cash burn (by our math) | $28.3M $22.6M last quarter |
| Cash funding outlook | Into 2029 prior: through 2029 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because encouraging early human data in a second disease is balanced by a tougher regulatory path in the lead program. In Factor VII deficiency, a single shot of sutacimig cut blood-clotting time by more than half in its first two patients. The bad news: Hemab launched its Phase 3 Glanzmann thrombasthenia trial as a single-arm study even though the US regulator recommended a randomized control group, creating a risk that the agency could demand another trial before approval.
The question now is whether the Phase 3 trial can show a large enough drop in bleeding to win approval without a control group, while higher doses prove safe across the pipeline. Either the drug cuts bleeding sharply enough to satisfy regulators on its own, or the lack of a control arm forces a costly delay. The December 2026 Factor VII data and early 2027 von Willebrand results will provide the next clinical proof points.
🐂 Bull Case
Sutacimig Shows First Human Proof in Second Disease
Sutacimig is Hemab's lead antibody therapy, designed to help blood clot by stabilizing a natural clotting protein called Factor VIIa and bringing it to platelets. After starting a Phase 3 study in Glanzmann thrombasthenia, a rare platelet disorder, the biotech group reported its first human results in a second rare condition, Factor VII deficiency.
- Clotting speed: prothrombin time, a measure of how fast blood clots, shortened by more than 50% from a baseline of at least 180 seconds in both treated patients
- Protein buildup: natural Factor VII(a) levels rose roughly fivefold and stayed high through day 22 in the first patient with detailed blood data
- Safety: side effects were mild and unrelated to the drug across both single-dose patients
These early findings matter because they prove the drug works as intended inside human patients with this specific deficiency, not just in laboratory tests. Sustaining the clotting protein for three weeks after one injection also supports a convenient dosing schedule. What to watch: updated Phase 2b results for all dosed patients at the medical meeting on December 14, 2026, which will show whether higher doses keep the same clean safety record.
Third Drug Enters Human Testing for Common Bleeding
Chief executive Benny Sørensen wants to "expand our development efforts for larger, underserved markets across coagulation disorders". His first two drugs target rare conditions with a few thousand patients, whereas HMB-003, a peptide drug that stops blood clots from breaking down too early, targets heavy menstrual bleeding affecting over 23 million American women.
In September, the company dosed the first healthy volunteer in a Phase 1 safety trial of HMB-003. It also reported that a single injection blocked clot breakdown for up to seven days in pigs and reduced heavy bleeding days in monkeys. Standard non-hormonal pills require frequent daily doses, so a weekly shot could draw wide use. What to watch: initial human trial results in mid-2027, which will test if the one-week duration holds true in people.
🐻 Bear Case
Phase 3 Trial Proceeds Against FDA Design Advice
Hemab started SOLARA, a Phase 3 study of sutacimig in 75 patients with Glanzmann thrombasthenia, a severe congenital bleeding disorder. Sørensen said the launch is "transitioning Hemab to a biotech company with clinical stage programs ranging from Phase 1 to Phase 3 across our portfolio". In this trial, doctors track each patient's bleeding for 24 weeks on standard care, then compare that against 48 weeks on weekly sutacimig injections.
However, the company disclosed a regulatory disagreement inside the trial announcement. "The FDA recommended that the Company consider a randomized controlled design." Management rejected that setup and chose a single-arm study where every patient gets the drug, citing wide differences in bleeding rates between patients and "the practical challenges of randomized trials in a rare disease".
Ignoring regulatory advice before starting a final-stage trial carries major risk. As the company admits in its risk disclosures, regulators "may not accept the results of SOLARA as substantial evidence supporting approval" and could demand another randomized study later. What to watch: patient enrollment updates following the fourth-quarter run-in start, and any future regulatory feedback on whether a larger reduction in bleeding is needed to overcome the single-arm design.
Clinical Trial Expansion Drives Rapid Cost Growth
Running three human trials at the same time is driving spending up fast. Total operating expenses rose 74% from a year ago to $29.8 million in the third quarter, led by research and development costs jumping 69% to $24.6 million on "the advancement of clinical programs" and new hiring.
By our math, operating cash outflow hit $28.3 million this quarter, up from $22.6 million in the second quarter. Management expects its $430.2 million cash pile to last "into 2029", which wording-wise is slightly tighter than last quarter's forecast of through 2029. By our math, exhausting that cash by early 2029 implies quarterly cash burn will rise by more than half to an average of $43 million as the 75-patient Phase 3 trial fills up. What to watch: fourth-quarter research spending as the first Phase 3 patients enter the 24-week observation period.
👓 Other Themes
Horizon Veteran Joins Board Ahead of Late-Stage Push
In September, Hemab appointed Keli Walbert to its board of directors and audit committee. Walbert previously served as executive vice president of US commercial operations at Horizon Therapeutics and helped launch rare and common disease drugs including Tepezza and Humira. Adding commercial expertise now prepares the board for drug pricing and launch planning as sutacimig enters Phase 3 testing.
💲 Other KPIs
Interest earned on cash and securities rose from $2.86 million last quarter and $0.22 million a year ago, thanks to the $317.2 million raised in the May initial public offering. By our math, this interest income covered 11.4% of the quarter's $29.8 million operating loss.
The basic and diluted share count rose 55.1% from 30.1 million in the second quarter and 0.95 million a year ago. The third quarter was the first full period reflecting the May public offering and preferred stock conversion, which mechanically reduced the net loss per share from $18.04 to $0.58.
🔮 Guidance
Cut slightly in wording. The drugmaker now says its $430.2 million in cash and securities will fund operations "into 2029", whereas last quarter's notes said through 2029 on $457.5 million. By our math, lasting 10 quarters into early 2029 allows an average cash burn of $43.0 million per quarter, up 52% from the third quarter's $28.3 million pace.
Unchanged. After sharing results from the first two single-dose patients in November, management set the full cohort poster presentation for the hematology conference on December 14, 2026. That date sits inside the earlier late 2026 or early 2027 window.
Unchanged. The biotech group plans to present additional data from the ongoing VELORA Pioneer trial at the European bleeding disorders congress in February 2027, hitting the back half of its prior late 2026 or early 2027 target.
Unchanged. Following the first volunteer dose in September 2026 and preclinical presentations set for December 13, 2026, the company still expects initial human safety and dosing results in mid-2027.
❓ Key Questions
What convinced management to decline the FDA's randomized trial advice?
The FDA recommended a randomized controlled design for the Phase 3 SOLARA study, yet Hemab chose a single-arm trial. Investors need to know what effect size or bleeding reduction threshold the agency indicated would be necessary to approve sutacimig without a control group.
How many patients are included in the December Factor VII presentation?
The November release covered only two patients dosed as of July 24, 2026, with full blood tracking in just one. Management did not disclose how many total patients and dose levels will appear in the December 14 poster.
Have any new blood-clotting side effects appeared in ongoing sutacimig trials?
In prior studies, three patients had moderate clotting events at higher drug exposure levels. As sutacimig moves into a 75-patient Phase 3 trial and higher Phase 2b cohorts, updates on clotting safety across all active trials are critical.
Why did the cash runway wording shift from through 2029 to into 2029?
Second-quarter notes pointed to funding through 2029, while the third-quarter release says into 2029. Management should clarify whether Phase 3 site startup or HMB-003 clinical work pulled up the expected cash burn schedule.